Kura Oncology at ESMO Congress 2025: Promising Cancer Therapies

Kura Oncology (NASDAQ:KURA) presented compelling clinical data at ESMO 2025 for its Farnesyl Transferase Inhibitor (FTI) program, showcasing Darlafarnib (KO-2806) and Tipifarnib. Darlafarnib monotherapy demonstrated encouraging safety and anti-tumor activity in HRAS mutant solid tumors. Notably, combination therapies yielded robust results: Darlafarnib with cabozantinib achieved 33-50% objective response rates in clear cell renal cell carcinoma, including in prior cabozantinib failures, with a manageable safety profile, while Tipifarnib with alpelisib showed nearly 50% ORR and durable responses in PIK3CA-altered head and neck cancer. Kura plans further development, including a Phase 1b for Darlafarnib/cabozantinib and dose escalation for Darlafarnib/adagrasib, anticipating a substantial market opportunity exceeding 200,000 patients by enhancing targeted therapies.

Analysis

Kura Oncology presented highly encouraging clinical data for its Farnesyl Transferase Inhibitor (FTI) program at ESMO 2025, focusing on Darlafarnib (KO-2806) and Tipifarnib. Darlafarnib monotherapy demonstrated a manageable safety profile and anti-tumor activity in HRAS mutant solid tumors across multiple dose levels (3-8mg), with some patients showing durability beyond 20 months. This next-generation FTI offers enhanced potency and optimized pharmacokinetic properties, including once-daily dosing.

The combination therapy results were particularly impactful. Darlafarnib combined with cabozantinib in renal cell carcinoma (RCC) showed objective response rates (ORR) of 33-50% in clear cell RCC, significantly exceeding cabozantinib monotherapy's expected 25-28% ORR, even in patients with prior cabozantinib failure. Similarly, Tipifarnib with alpelisib in PIK3CA-altered head and neck cancer achieved nearly 50% ORR and durable responses, a substantial improvement over alpelisib monotherapy's near 0% ORR.

These combinations exhibited favorable safety profiles with no apparent overlapping toxicities, allowing for dose escalation of partner drugs. Kura plans further development, including a Phase 1b study for Darlafarnib/cabozantinib and dose escalation for Darlafarnib/adagrasib, targeting a potential market of over 200,000 patients. The FTI mechanism appears to enhance the effectiveness of targeted therapies by inhibiting mTOR signaling rebound, positioning Kura's pipeline for significant impact.

Key Decisions for Investors

• Investors should closely monitor the progression of Kura Oncology's FTI program, particularly the upcoming Phase 1b data for Darlafarnib/cabozantinib and preliminary data for Darlafarnib/adagrasib, as these represent key near-term catalysts.
• Given the strong clinical efficacy and favorable safety profiles demonstrated by Darlafarnib and Tipifarnib in combination therapies, Kura's FTI platform appears well-positioned to enhance existing targeted treatments and address a significant unmet medical need across multiple cancer types.
• While clinical results are promising, investors should also assess the company's financial strategy and potential for strategic collaborations or business development to capitalize on the estimated 200,000+ patient market opportunity.